Midgestation maternal serum 25-hydroxyvitamin D level and soluble fms-like tyrosine kinase 1/placental growth factor ratio as predictors of severe preeclampsia. 2011

Padmashree Chaudhury Woodham, and Julia E Brittain, and Arthur M Baker, and D Leann Long, and Sina Haeri, and Carlos A Camargo, and Kim A Boggess, and Alison M Stuebe
Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, 3010 Old Clinic Building, CB#7516, Chapel Hill, NC 27599-7516, USA. pchaudh@gmail.com

Recent studies have shown that low serum 25-hydroxyvitamin D (25[OH]D) level is a risk factor for preeclampsia. The clinical significance of in vitro findings that vitamin D regulates vascular endothelial growth factor production is unclear. We sought to determine whether there is an association between midgestation serum 25(OH)D levels and angiogenic factor activity and to compare their predictive value for the development of severe preeclampsia. We conducted a nested case-control study of women with severe preeclampsia (n=41) versus women with uncomplicated term birth (n=123) who had second trimester genetic screening (15-20 weeks). Using banked frozen serum, we measured levels of 25(OH)D, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1, and placental growth factor and compared their correlations and predictive values. We found no correlation between serum 25(OH)D and angiogenic factors levels. 25(OH)D alone was comparable to vascular endothelial growth factor and soluble fms-like tyrosine kinase 1/placental growth factor ratio as a predictive marker for severe preeclampsia. A composite of both 25(OH)D level and soluble fms-like tyrosine kinase 1/placental growth factor ratio was more predictive than either alone (area under curve: 0.83 versus 0.74 and 0.67, respectively). In conclusion, combining midpregnancy 25(OH)D level with soluble fms-like tyrosine kinase 1/placental growth factor ratio provides a better prediction for the development of severe preeclampsia.

UI MeSH Term Description Entries
D011225 Pre-Eclampsia A complication of PREGNANCY, characterized by a complex of symptoms including maternal HYPERTENSION and PROTEINURIA with or without pathological EDEMA. Symptoms may range between mild and severe. Pre-eclampsia usually occurs after the 20th week of gestation, but may develop before this time in the presence of trophoblastic disease. Toxemias, Pregnancy,EPH Complex,EPH Gestosis,EPH Toxemias,Edema-Proteinuria-Hypertension Gestosis,Gestosis, EPH,Hypertension-Edema-Proteinuria Gestosis,Preeclampsia,Preeclampsia Eclampsia 1,Pregnancy Toxemias,Proteinuria-Edema-Hypertension Gestosis,Toxemia Of Pregnancy,1, Preeclampsia Eclampsia,1s, Preeclampsia Eclampsia,EPH Toxemia,Eclampsia 1, Preeclampsia,Eclampsia 1s, Preeclampsia,Edema Proteinuria Hypertension Gestosis,Gestosis, Edema-Proteinuria-Hypertension,Gestosis, Hypertension-Edema-Proteinuria,Gestosis, Proteinuria-Edema-Hypertension,Hypertension Edema Proteinuria Gestosis,Of Pregnancies, Toxemia,Of Pregnancy, Toxemia,Pre Eclampsia,Preeclampsia Eclampsia 1s,Pregnancies, Toxemia Of,Pregnancy Toxemia,Pregnancy, Toxemia Of,Proteinuria Edema Hypertension Gestosis,Toxemia Of Pregnancies,Toxemia, EPH,Toxemia, Pregnancy,Toxemias, EPH
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011257 Pregnancy Proteins Proteins produced by organs of the mother or the PLACENTA during PREGNANCY. These proteins may be pregnancy-specific (present only during pregnancy) or pregnancy-associated (present during pregnancy or under other conditions such as hormone therapy or certain malignancies.) Placental Proteins,Proteins, Placental,Proteins, Pregnancy
D011262 Pregnancy Trimester, Second The middle third of a human PREGNANCY, from the beginning of the 15th through the 28th completed week (99 to 196 days) of gestation. Midtrimester,Pregnancy, Second Trimester,Trimester, Second,Midtrimesters,Pregnancies, Second Trimester,Pregnancy Trimesters, Second,Second Pregnancy Trimester,Second Pregnancy Trimesters,Second Trimester,Second Trimester Pregnancies,Second Trimester Pregnancy,Second Trimesters,Trimesters, Second
D005260 Female Females
D005820 Genetic Testing Detection of a MUTATION; GENOTYPE; KARYOTYPE; or specific ALLELES associated with genetic traits, heritable diseases, or predisposition to a disease, or that may lead to the disease in descendants. It includes prenatal genetic testing. Genetic Predisposition Testing,Genetic Screening,Predictive Genetic Testing,Predictive Testing, Genetic,Testing, Genetic Predisposition,Genetic Predictive Testing,Genetic Screenings,Genetic Testing, Predictive,Predisposition Testing, Genetic,Screening, Genetic,Screenings, Genetic,Testing, Genetic,Testing, Genetic Predictive,Testing, Predictive Genetic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000072483 Placenta Growth Factor An angiogenic protein belonging to the Vascular Endothelial Growth Factor family of growth factors originally isolated and cloned from human placental cDNA library. There are four isoforms of PLGF 1-4 which result from alternative splicing. Placenta Growth Factor is secreted as a glycosylated homodimer which acts as a mitogen for endothelial cells, and its expression is markedly upregulated during hypoxia and in tissue inflammation and cancer. Placenta Growth Factor, PLGF-1 Isoform,Placenta Growth Factor, PLGF-2 Isoform,Placenta Growth Factor, PLGF-3 Isoform,Placenta Growth Factor, PLGF-4 Isoform,Factor, Placenta Growth,Growth Factor, Placenta,Placenta Growth Factor, PLGF 1 Isoform,Placenta Growth Factor, PLGF 2 Isoform,Placenta Growth Factor, PLGF 3 Isoform,Placenta Growth Factor, PLGF 4 Isoform
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Padmashree Chaudhury Woodham, and Julia E Brittain, and Arthur M Baker, and D Leann Long, and Sina Haeri, and Carlos A Camargo, and Kim A Boggess, and Alison M Stuebe
January 2010, Acta obstetricia et gynecologica Scandinavica,
Padmashree Chaudhury Woodham, and Julia E Brittain, and Arthur M Baker, and D Leann Long, and Sina Haeri, and Carlos A Camargo, and Kim A Boggess, and Alison M Stuebe
October 2019, Journal of gynecology obstetrics and human reproduction,
Padmashree Chaudhury Woodham, and Julia E Brittain, and Arthur M Baker, and D Leann Long, and Sina Haeri, and Carlos A Camargo, and Kim A Boggess, and Alison M Stuebe
October 2012, Hypertension (Dallas, Tex. : 1979),
Padmashree Chaudhury Woodham, and Julia E Brittain, and Arthur M Baker, and D Leann Long, and Sina Haeri, and Carlos A Camargo, and Kim A Boggess, and Alison M Stuebe
April 2014, The Malaysian journal of pathology,
Padmashree Chaudhury Woodham, and Julia E Brittain, and Arthur M Baker, and D Leann Long, and Sina Haeri, and Carlos A Camargo, and Kim A Boggess, and Alison M Stuebe
May 2020, Hypertension in pregnancy,
Padmashree Chaudhury Woodham, and Julia E Brittain, and Arthur M Baker, and D Leann Long, and Sina Haeri, and Carlos A Camargo, and Kim A Boggess, and Alison M Stuebe
December 2021, The journal of obstetrics and gynaecology research,
Padmashree Chaudhury Woodham, and Julia E Brittain, and Arthur M Baker, and D Leann Long, and Sina Haeri, and Carlos A Camargo, and Kim A Boggess, and Alison M Stuebe
November 2011, Hypertension (Dallas, Tex. : 1979),
Padmashree Chaudhury Woodham, and Julia E Brittain, and Arthur M Baker, and D Leann Long, and Sina Haeri, and Carlos A Camargo, and Kim A Boggess, and Alison M Stuebe
February 2015, Journal of the American Society of Hypertension : JASH,
Padmashree Chaudhury Woodham, and Julia E Brittain, and Arthur M Baker, and D Leann Long, and Sina Haeri, and Carlos A Camargo, and Kim A Boggess, and Alison M Stuebe
October 2019, Placenta,
Padmashree Chaudhury Woodham, and Julia E Brittain, and Arthur M Baker, and D Leann Long, and Sina Haeri, and Carlos A Camargo, and Kim A Boggess, and Alison M Stuebe
February 2004, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!